DXO
DXO (decapping exoribonuclease, also known as DOM3L or DOM3Z) is a nuclear enzyme that removes non-canonical 5'-end caps from RNA and then degrades the resulting transcript. It acts on NAD-capped RNAs and on incompletely capped pre-mRNAs. Browse Assay Genie's current range of DXO research reagents below, or read on for the biology behind the target.
DXO is a decapping enzyme for NAD-capped RNAs. It specifically hydrolyses the nicotinamide adenine dinucleotide (NAD) cap from a subset of RNAs, removing the entire NAD moiety from the 5'-end. The NAD cap is present on some RNAs and snoRNAs and, in contrast to the canonical 5'-end N7 methylguanosine (m7G) cap, it promotes mRNA decay. DXO preferentially acts on NAD-capped transcripts in response to environmental stress.
The enzyme is also a non-canonical decapping enzyme. It removes the entire cap structure of m7G-capped or incompletely capped RNAs and mediates their subsequent degradation. It specifically degrades pre-mRNAs with a defective 5'-end m7G cap and forms part of a pre-mRNA capping quality control. It is active towards unmethylated 5'-end-capped RNA (cap0) but not towards the 2'-O-ribose methylated m7G cap (cap1). Unlike the canonical decapping enzymes DCP2 and NUDT16, which cleave within the triphosphate linkage, DXO releases the entire cap structure GpppN and a 5'-end monophosphate RNA. Its 5'-3' exoribonuclease activity then degrades that RNA. DXO also has RNA 5'-pyrophosphohydrolase activity, releasing pyrophosphates from the 5'-end triphosphate, and shows decapping activity towards FAD-capped RNAs and, in vitro, dpCoA-capped RNAs.
The human DXO gene lies in the major histocompatibility complex (MHC) class III region on chromosome 6. NCBI notes its ubiquitous expression and its conservation in simple and complex eukaryotes, which suggests a housekeeping role. The protein belongs to the DXO/Dom3Z family and was previously named DOM-3 homolog Z (C. elegans). Mouse and rat orthologues are both named Dxo.
DXO degrades pre-mRNAs with a defective 5'-end m7G cap, making it a key enzyme for studying pre-mRNA capping quality control.
DXO removes the NAD cap from a subset of RNAs and snoRNAs, which makes it central to work on non-canonical RNA caps.
Combining decapping with 5'-3' exoribonuclease activity, DXO links cap removal to RNA degradation, unlike DCP2 and NUDT16, which cleave within the triphosphate linkage.
DXO preferentially acts on NAD-capped transcripts in response to environmental stress, supporting research into how RNA decay adapts to cellular conditions.
DXO is a nuclear decapping enzyme that removes the NAD cap from a subset of RNAs. It also removes the entire cap from incompletely capped m7G RNAs, then degrades them through 5'-3' exoribonuclease activity. It takes part in pre-mRNA capping quality control and has RNA 5'-pyrophosphohydrolase activity.
DXO stands for decapping exoribonuclease. UniProt lists the protein as decapping and exoribonuclease protein, and aliases include DOM3L and DOM3Z. Earlier names were DOM-3 homolog Z (C. elegans). The protein belongs to the DXO/Dom3Z family, which explains the older symbols.
Yes. NCBI reports that DXO is ubiquitously expressed and conserved in both simple and complex eukaryotes, suggesting a housekeeping role. Mouse and rat each have an orthologue named Dxo. Check the datasheet of any product for its validated reactivity.
Canonical decapping enzymes and other RNA decay factors that contrast with or complement DXO activity.
Gene and protein annotations from HGNC, NCBI Gene and UniProt O77932; product specifications from Assay Genie datasheets.